Symbols

IMCR

Immunocore·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 3

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

EPS Beats Expectation

Price Hits 52-week Low

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IMCR

Immunocore Holdings Plc

A commercial-stage biotechnology company that developing immunotherapies with T-cell receptors to treat cancer, infectious and autoimmune

Industry

Biological Technology

Established Date

01/07/2021

Listing Date

02/05/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

493

Fiscal Year Ends

12-31

Website

www.immunocore.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

92 Park Drive, Milton Park, Abingdon, Oxfordshire , United Kingdom OX14 4RY

Business

Introduction

Immunocore Holdings plc was incorporated on January 7, 2021 under the laws of England and Wales. The company is a commercial-stage biotechnology company that creates and delivers transformative immunomodulatory drugs that fundamentally improve outcomes for patients with cancer, infectious diseases and autoimmune diseases. Leveraging the Company's proprietary, flexible, off-the-shelf ImmTAX platform, the Company is developing a deep pipeline across multiple therapeutic areas, including clinical-stage programs in oncology and infectious diseases, advanced preclinical programs in autoimmune diseases, and early stage preclinical programs across three therapeutic areas. In 2022, the Company received FDA, European Commission and health authorities approval for the lead product KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.

Company Financials

EPS

IMCR has released its 2025 Q3 earnings. EPS was reported at 0, versus the expected -0.24, beating expectations. The chart below visualizes how IMCR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IMCR has released its 2025 Q3 earnings report, with revenue of 103.69M, reflecting a YoY change of 29.22%, and net profit of -177.00K, showing a YoY change of -102.03%. The Sankey diagram below clearly presents IMCR's revenue sources and cost distribution.